Fair Value Calculator Fair Value Calculator
EN DE

1515 (1515) Fair Value & Analysis

Healthcare · Market cap HK$3.0B

1 1515 1515 · HK
PriceHK$2.38
Fair ValueHK$7.70
Upside+223.5%
Quality51/100
Watch 1515 for free — get notified when fair value or trend changes. Watch for free
Evidence: Medium Range HK$5.77 – HK$9.62

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −5.8% over the past month.

Price vs Fair Value (12 months)

HK$4.34 HK$2.29 Fair Value HK$7.70 Jun 2025 Jul 2026

12‑month range HK$2.29 – HK$4.34 · fair‑value band HK$5.77 – HK$9.62 · the HK$2.38 price screens below the HK$7.70 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1515 (1515) currently trades at HK$2.38, while our model-based Fair Value estimate is HK$7.70 — implying the stock looks roughly 223.5% undervalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 1515 generated revenue of HK$9.2B at a net margin of 5.4%. Revenue declined 4.7% year over year. It earns a return on equity of 7.2%. The balance sheet holds a net cash position of HK$178M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$9.2B
Revenue growth (YoY) -4.7%
Net margin 5.4%
Return on equity 7.2%
Free cash flow HK$844M FY2025
P/E ratio 5.3
More key figures
Operating margin 4.1%
EPS (TTM) HK$0.2700
Dividend yield 5.6%
EPS growth (YoY) +15.0%
Net cash HK$178M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1515 reported revenue of HK$9.2B in FY2025 versus HK$4.4B in FY2021, a compound +19.8%/yr. Reported net income was HK$496M in FY2025, compounding +4.4%/yr from FY2021.

Revenue +19.8%/yr
FY21 HK$4.4B
FY22 HK$7.9B
FY23 HK$10.1B
FY24 HK$9.9B
FY25 HK$9.2B
Net income +4.4%/yr
FY21 HK$418M
FY22 HK$266M
FY23 HK$258M
FY24 HK$566M
FY25 HK$496M

Is 1515 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc H1CA34 R$96.00 R$25.67 -73%
Fresenius SE FSNUY $11.30 $8.61 -24%
5225 5225 8.67 MYR 3.08 MYR -64%
IHHHF IHHHF $1.71 $0.7400 -57%
Tenet Healthcare Corporation THC $178.75 $300.86 +68%
Rede D'Or São Luiz S.A RDOR3 R$33.83 R$46.94 +39%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 1515 (1515) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$7.70 versus a price of HK$2.38 — about +224% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 1515?
Our model-based fair value for 1515 is HK$7.70 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$2.38.
What is the quality score of 1515?
1515 has a Quality Score of 51/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 1515 (1515)?
1515 reported trailing-twelve-month revenue of about HK$9.2B (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 1515?
The net profit margin of 1515 is about 5.4%, meaning it keeps roughly 5.4% of revenue as net income. Based on the latest reported figures.
Does 1515 pay a dividend?
1515 currently shows a dividend yield of about 5.63% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.